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ABSTRACT 
Dysmenorrhea is the most common gynecological problem faced by 
women during their adolescence and also in reproductive age which 
causes significant discomfort and anxiety for the women. In modern 
medicine dysmenorrhea is treated by oral contraceptive pills, non-
steroidal anti-inflammatory drugs, antispasmodic, analgesics etc. This 
treatment may relieve symptoms of dysmenorrhoea but it does not 
address the root of the problem. Long term use of these causes side 
effects. So to minimize these complications, an attempt is made to find 
out safe, potent, cost effective remedy from Ayurveda for the 
management of Kashtartava. In Ayurveda Kashtartava, term which is 
being used for the condition where in a women may suffer with pain 
during menstruation. Pain is the main feature of Kashtartava, so it has 
strong relation with Vata Dosha. For the management of this vitiated 
Vata, treatment that effect direct on the place of Vata should be selected 
therefore by administering Basti to normalize vitiation of Vata and 
proper measures to correct the Agnivikara should be the prime 
objectives of the treatment. Keeping this point in view, the present 
clinical trial, a clinical study to evaluate efficacy of “Trivritadi Taila 
Anuvasan-Basti” in the management of Kashtartava with special 
reference to Primary Dysmenorrhea was taken. Trivritadi Taila 
Anuvasan-Basti due to the properties of Anulomana and Vatahara may it 
effectively brings down the Pratiloma Gati Vata which is mentioned in 
A.S.Utt. 39/29 for Udavartini Yonivyapad, which is one of the main disease 
conditions compares with Kashtartava (Primary dysmenorrhoea). 
Results were assessed on the basis of improvement in the subjective 
parameters. The study reveals that patients of Kashtartava after 
treatment showed significant improvement in chief complaints, from the 
above trial it is clear that Trivritadi Taila Anuvasan-Basti can be used as a 
safe and effective therapeutic agent in the management of Kashtartava. 
 
INTRODUCTION 
Dysmenorrhea is critical global health issue 
in reproductive age women, as it causes frequent 
short-term work and school absenteeism and has a 
significantly negative effect on daily activities.[1] 
Dysmenorrhoea is defined as painful menstruation 
so as to incapacitate day to day activities.[2] Primary 
dysmenorrhea is extremely common, especially 
among adolescents. Primary dysmenorrhea refers 
to menstrual pain without pelvic pathology.[3] The 
prevalence of primary dysmenorrhea was 85.4% of 
these, 28.5% had mild, 38.1% moderate and 18.8% 
severe dysmenorrhea pain.[4] In Ayurveda, 
Kashtartava is a broad term which covers all 
problem and ailments that a woman may suffer 
during or around menstruation. It includes both 
primary and secondary types of dysmenorrhea. For 
the present study, only primary dysmenorrhoea is 
taken with Kashtartava to exclude the pathological 
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cases, but, in fact, no disease can be primary 
according to Ayurvedic principles, as each and 
every disease has its certain pathogenesis. Still it 
makes the study easier and the data can be 
analyzed easily, if a single type origination of 
disease is taken under consideration. Acharya 
Charaka has mentioned that Yoniroga can’t occur 
without vitiation of Vata. As Vata is main causative 
factor it should be treated first. [5] According to 
Ayurveda, pain is an indication of Vata Vikriti – 
Vaatadrite Nasti Ruja.[6] Pain is the main feature of 
Kashtartava, so it has strong relation with Vata 
Dosha. According to Acharya Sushruta, Apana Vayu 
and Vyana Vayu are mainly responsible for Artava 
Utpatti.[7] Normal menstruation is the function of 
the Apanavata.[8] For the production of Artava, 
Apana and Vyana work in coordination with each 
others. Vyana Vayu has control over the muscles 
which brings about actions such as contraction, 
relaxation, extension, flexion etc. Contraction, 
relaxation of the uterus and its related organs is the 
function of Vyana Vayu, after which Artava is 
expelled out by Anulomana kriya of Apana Vayu. If 
women have any difficulty in menstruation it 
indicates Apana and Vyana Vatadushti. So 
Kashtartava is considered as a Tridoshaja Vyadhi 
with Vata predominance especially due to 
derangement of Apana and Vyana Vata. Basti has 
being mentioned as one of the best therapeutic 
procedure for alleviation of vitiated Vata.[9] Out of 
all Sthanas of Vata the Pakvadhan is dominant and 
Basti can be considered as the closest path to reach 
Pakvashaya than other treatment procedures. 
Matra Basti is a type of Anuvasana Basti and the 
simplest type of Basti. So it is selected for the 
present study due to its indication in any season, at 
any age, without much restriction. [10] In addition 
Agnivikara induces vitiation of Apana Vata since the 
three Vayus- Prana, Apana and Samana, located 
normally in their respective places initiate and 
preserve the metabolic power of the body. [11] The 
selected drug is Vatashamaka and correct the 
Agnivikara mentioned by the classics and Trivritadi 
Taila Anuvasan-Basti due to the properties of 
Anulomana and Vatahara may it effectively brings 
down the Pratiloma Gati Vata which is mentioned in 
A.S.Utt. 39/29[12] for Udavartini Yonivyapad which is 
one of the main diseases conditions compares with 
Kashtartava (Primary dysmenorrhoea).  
Drug used for Present Study  
For the present study “Trivritadi Taila 
Anuvasana Basti” was used. The formulation was 
prepared by NIA, Jaipur pharmacy according to 
classical textual mode of preparation of oil.  
 
AIM AND OBJECTIVES 
1. To study etiopathogenesis of Kashtartava as per 
the classical and modern literature.  
2. To evaluate the therapeutic efficacy of Trivritadi 
Taila Anuvasana Basti in the management of 
Kashtartava.  
MATERIALS AND METHODS 
Design of the study 
The method adopted in present study is 
Randomized, Clinical, Open study. 
1. Study type: Interventional 
2. Masking: Open label 
3. Purpose: Treatment 
4. Timing: 2 consecutive cycles. 
5. End point: Efficacy 
6. Subjects: Minimum of 15 patients  
Selection of cases: Total 16 clinically diagnosed 
and confirmed cases of Primary Dysmenorrhoea 
were registered for the present clinical trial  
 Source of data: The cases were selected from the 
O.P.D. / I.P.D. of P.G. Department of Prasuti-Striroga, 
National Institute of Ayurveda (N.I.A.) Hospital, 
Jaipur.  
Criteria for selection of patients 
Inclusion criteria 
 Patients coming with chief complaint of 
Kashtartava with scanty or average amount of 
menses along with associated symptoms. 
 Patients in age group of 16 to 30 years. 
 Patients with H/O using analgesics during 
menses. 
Exclusion criteria   
 The patient suffering from malignant systemic 
disorders, specially those are mentioned as 
Asadhya vyadhi as per clinical text of Ayurveda 
will be excluded. 
 Subjects having organic pathology of uterus and 
adnexa eg.-Fibroid uterus, carcinoma of 
endometrium etc. 
Criteria for withdrawal 
 If any serious condition develops during the 
course of trial which requires urgent 
treatment. 
 If the patient wants to withdraw from clinical 
trial by herself. 
 Patient with irregular follow up and non-
compliance. 
Investigation: Laboratory test of blood, urine and 
USG were carried out before treatment to rule out 
any other pathological conditions. 
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Method of Data Collection 
 The method adopted in present study is clinical, 
open study with a pre-test & post-test design.  
 16 patients are selected for the trial, were 
Trivritadi Taila Anuvasan- Basti (Matra-Basti), 
administered per rectum 60ml/day for 7 
alternate days, Basti started 14 days before 
onset of expected menstrual cycle and same 
process done in next consecutive menstrual 
cycles. 01 patient discontinued and 15 patients 
were completed the trial.  
 Duration for clinical trial: The trial will be 
carried out for 60 days in two consecutive 
menstrual cycles. The assessment was done 
after each cycle on 5th day of cycle and follow-
up for the one next menstrual cycle. 
 Criteria of assessment: A special scoring 
pattern was applied in symptoms and 
associated complaints.  
 Follow up study: Clinical assessment will be 
done after completion of 2 consecutive 
menstrual cycles. 
 The parameters of signs and symptoms were 
scored on the basis of standard method of 
statistical analysis. 
Method of Administration of Matra Basti 
The patient was asked to take light meal, 
neither too Snigdha nor too Ruksha and not more 
than 3/4th of the usual quantity. The patient was 
advised to take left lateral position with left lower 
extremity straight and right lower extremity flexed 
on knee and hip joint. The patient was asked to 
keep his left hand below the head. 60ml of 
lukewarm Taila was taken in enema syringe. 
Rubber catheter oleated with Taila was attached to 
enema syringe. After removing the air from enema 
syringe, rubber catheter was administered into the 
anus of the patient up to the length of 4 inches. The 
patient was asked to take deep breath while 
introducing the catheter and drug. 
Criteria of assessment 
The improvement in the patient was 
assessed mainly on the basis of relief in the signs 
and symptoms of the disease. To assess the effect of 
therapy objectively, all the signs and symptoms 
were given scoring depending upon their severity. 
Dysmenorrhoea, the cardinal symptom assessed on 
it severity and duration of persist. Other associated 
symptoms according to Ayurveda as well as per 
modern, also assessed by the scoring method. 
 
 
Assessment of Pain (Dysmenorrhoea): A special 
Scoring Pattern was applied in symptoms: 
Pain Intensity Grade 
Absent 0 
Mild (pain do not interfere with daily 
activity) 
1 
Moderate(daily activity hampers, 
relieves with analgesics) 
2 
Severe (do not relieved by 
analgesics) 
3 
  
Duration of Pain Grade 
Absent 0 
Pain for one day (for few hours) 1 
Pain for one day(for whole day) 2 
Pain for>or=2 days 3 
  
Nature of Pain Grade 
Absent 0 
Occasional 1 
Dull 2 
Spasmodic 3 
 
Menstrual Flow Duration Grade 
1 day 3 
< or =2 days 2 
3-4 days 1 
> or =5 days 0 
  
Menstrual Flow Amount Grade 
Scanty (spotting) 3 
Average (1-2 pads) 2 
Normal (3-4 pads) 1 
Excessive (5 pads or more) 0 
 Visual Analog Scale  
         
       0      1       2       3        4       5       6      7        8     9 
And further it is assessed as follows 
7 - 10 severe pain Grade 3 
6 - 4 moderate pain Grade 2 
1 - 3 mild pain Grade 1 
0 no pain Grade 0 
AYUSHDHARA, 2019;6(5):2333-2339 
 AYUSHDHARA | September - October 2019 | Vol 6 | Issue 5  2336 
Rating scale for the assessment of improvement 
in the symptoms after therapy 
Percentage of relief effect 
Mild Relief 
(0 to 25%) relief in the signs and 
symtoms 
Moderate 
relief 
(>25 to 50%) relief in the signs 
and symtoms 
Significant 
Relief 
(>50 to 75%) relief in the 
signsand symtoms 
Excellent 
Relief 
(>75%) relief in the signs and 
symtoms 
OBSERVATIONS 
 Total 15 patients included in trial in which 
33.33% of the patients were in the age group of 16-
20yrs, 33.33% of the patients in age 21-25yrs and 
also 33.33% of the patients in age 26-30yrs. Most 
i.e. 66.67% of the patients included in trial were 
belongs to Hindu religion, 60% patients were 
housewives, 53.33% of the patients were married, 
73.33% of the patients were from lower middle 
class. Pertaining to personal history it is fond that; 
66.67% of the patients with the habit of vegetarian 
diet, 86.67% of the patients addicted to tea, 80% of 
the patients with normal sleep and 80% of the 
patients with constipated bowel habit, 66.67% of 
the patients had Mandagni, 66.67% of the patients 
had Krurakostha. From menstrual history it is about 
that, 53.33% of the patient’s menarche onset was in 
the age of 14yrs, 66.67% of the patients had regular 
menstruation, 80% of the patients had moderate 
amount of menstrual blood loss, 70% patients were 
having 3-4 days of duration of menses, 53.33% of 
the patients were having 28-30 days of interval of 
menstrual cycle. From pain wise history, it is 
observed that, in 60% patients pain was at lower 
abdomen, lower backache and radiating to thigh, 
53.33% of the of patients having spasmodic type of 
pain and 60% of the patients having duration of 
pain for = or >2 days.  
RESULTS 
Table 1: Shows the pattern of clinical recovery in Subjective Parameters in 15 patients 
S. 
No. 
Symptoms 
Mean 
Dif. 
% of 
Change 
SD SE P Result 
BT AT 
1.  Pain Intensity 2.267 0.867 1.400 61.75% 0.507 0.130 <0.0001 E.S. 
2.  Pain Duration 2.600 0.933 1.667 64.11% 0.723 0.186 < 0.0001 E.S. 
3.  Nature of Pain 2.333 1.067 1.267 54.30% 0.457 0.118 <0.0001 E.S. 
4.  Flow Duration 1.000 0.8667 0.133 13.33% 0.516 0.133 0.9999 N.S. 
5.  Flow Amount 1.933 1.467 0.467 24.16% 0.516 0.133 0.0156 S. 
6.  Associated Symptoms 2.000 0.0.467 1.533 76.65% 0.516 0.133 <0.0001 E.S. 
7.  VAS Scale 2.267 1.200 1.067 47.07% 0.593 0.153 0.0002 E.S. 
8.  
Wong Backer facial 
grimace scale 
2.267 1.067 1.200 52.39% 0.560 0.144 0.0001 E.S. 
E.S. = Extremely Significant, S. = Significant, N.S. = Non Significant 
Extremely significant results are shown on Pain Intensity, Pain Duration, Nature of Pain, Associated 
symptoms, VAS Scale and Wong Baker facial grimace scale. Results on Flow Amount found significant and 
non-significant result found on Flow Duration. 
Table 2: Shows the pattern of clinical recovery in various Associated Symptoms in 15 patients 
S.No Symptoms 
Mean 
Dif. 
% of 
Relief 
SD SE P Results 
BT AT 
1.  Nausea 0.800 0.067 0.733 91.66% 0.457 0.118 0.0010 E.S. 
2.  Vomiting 0.600 0.067 0.533 88.88% 0.516 0.133 0.0078 V.S 
3.  Fatigue 0.800 0.067 0.733 91.66% 0.457 0.118 0.0010 E.S. 
4.  Headache 0.600 0.133 0.466 77.78% 0.516 0.133 0.0156 S. 
5.  Fainting 0.133 0.067 0.067 50.03% 0.258 0.067 > 0.999 N.S. 
6.  Sweat 0.333 0.133 0.200 60.00% 0.414 0.107 0.2500 N.S. 
Renu et al. Efficacy of Trivritadi Taila Anuvasana Basti in the Management of Kashtartava  
 AYUSHDHARA | September - October 2019 | Vol 6 | Issue 5  2337 
E.S. = Extremely Significant, V.S. = Very Significant, S. = Significant, N.S. = Non Significant 
Extremely significant results are shown on Nausea, Fatigue and Constipation. Very significant results 
obtained on Vomiting and Vaginal discharge. Significant results are shown on Headache and Breast 
tenderness. Results on Fainting, Sweat and Diarrhoea were found Non-significant. 
Table 3: Shows the % improvement of symptoms 
S.No. Cardinal Symptoms Result (%) 
1 Nausea 91.66% 
2 Vomiting 88.88% 
3 Fatigue 91.66% 
4 Headache 77.78% 
5 Fainting 50.03% 
6 Sweat 60.00% 
7 Diarrhoea 50.03% 
8 Constipation 91.66% 
9 Vaginal Discharge 75.00% 
10 Breast Tenderness 75.00% 
11 Pain Intensity 61.75% 
12 Pain Duration 64.11% 
13 Nature of Pain 54.30% 
14 Flow Duration  13.33% 
15 Flow Amount 24.16% 
16 Associated Symptoms 76.65% 
17 VAS Scale 47.07% 
18 Wong Baker Facial Grimace Sale 52.93% 
 Average % of relief  63.67% 
Table 4: Overall Effect of Therapy 
S. No. Effect of therapy Result 
Patients 
No. % 
1 Mild (0 to 25%) 00 0.00% 
2 Moderate (>25 to 50%) 02 13.33% 
3 Significant (>50 to 75%) 08 53.33% 
4 Excellent (>75%) 05 33.33% 
DISCUSSION 
Mode of action of Trivritadi Taila 
Trivrita: Katu, Teekshana and Ushana properties 
lead to Deepana and Amapachana and than Sroto 
Shodhana while Virechana effect leads to clearance 
of Margavarodha and Pakvashaya. Thus Apana-
vaigunya is corrected. Anti-inflammatory activity 
helps in pacifying the pain in dysmenorrhoea. 
Trivirita is Sukhavirechaka and pacifies Kapha and 
Pitta Dosha, hence it manages Apanavaigunya by 
removing obstruction caused by Pitta and Kapha i.e. 
breaks the Margavrodha type of pathogenesis as 
explained in Udavartini Yonivyapada. 
7.  Diarrhoea 0.133 0.067 0.067 50.03% 0.258 0.067 > 0.999 N.S. 
8.  Constipation 0.800 0.067 0.733 91.66% 0.447 0.118 0.0010 E.S. 
9.  Vaginal Discharge 0.800 0.200 0.600 75.00% 0.507 0.130 0.0039 V.S. 
10.  Breast Tenderness 0.533 0.133 0.400 75.00% 0.507 0.130 0.0313 S. 
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Dashamoola: Dashmoola as the name suggests 
contains roots of ten different plants. Of these, five 
are known as Brihat panchmoola and the remaining 
as Laghu panchmoola. Acharya Charaka has used 
the term Dashamoola at various places but the 
drugs of Dashamoola have been depicted in 
Shothahara Dashemani[13] and Pancha-Pancha-
moola.[14] Acharya Sushruta[15] coined the very term 
for the first time which includes Laghu and Brihat 
panchmoola. 
Qualities and uses of Dashamoola: Acharya 
Charaka has appraised the Dashamoola as 
Shothahara (the one which is either anti-
inflammatory and reduce oedema), while Acharya 
Sushruta has apprised these as Kaphapittaanila-
hara, Shwasahara, Aampachaka and Sarvajava-
rahara.[16]  
 Tila Taila: Tila Taila has all the qualities that are 
opposite to Vata Dosha e.g. it is Guru, Snigdha, 
Madhura and Ushna. Its Ushana Virya results in 
Amapachana hence treat the obstructed channels 
while rest of the properties enables it to act as 
Dhatuposhaka. Taila is also regarded as the best 
Vata pacifier. All these qualities of Tila Taila are 
also regarded as the best Vata pacifier. All these 
qualities of Tila enable it to regulate the vitiated 
Vata when its obstruction is removed by the 
Trivrita ingredient. Taila carries the whole potency 
of drug in it. Taila (Lipid soluble) travels directly 
through the cell membrane (passive diffusion) 
because of homogeneity between the drug and cell 
membrane. The cell membrane provides free entry 
of the drug. Further the mild temperature of oil at 
the time of administration enhances its diffusion. 
Mode of action of Matra Basti on Kashtartava 
Matra Basti has both local and systemic 
effects. It causes Vatanulomana thereby 
normalizing Apana Vata. Mode of action of Matra 
Basti is defined in Ayurvedic classics very well. 
Acharya have explained its mode of action on 
Ayurvedic principles of Dosha and Dosha-Dushya 
Sammurchhana. Acharya Sushruta[17] says that the 
Virya of Basti administered through the Basti 
reaches the whole body through the channels 
(Srotas) as the active principles in the water when 
poured at the root of the tree reaches the whole 
plant. This definition explains how Basti acts on 
whole the body after reaching in the gastro-
intestinal tract. Spasm caused by vitiated Apana and 
Vyana Vayu causing obstruction to the flow of 
menstrual blood is the general underlying 
pathology. Tail enters to the Srotus and removes the 
Sankochana (Spasm) by virtue of its Snigdha 
Sukshama Vyavayi and Vikashi etc., fast spreading 
nature. Basti Dravya normalizes the function of Vata 
by pacifying it after reaching all over the body. Its 
contents act through their different chemical 
constituents to restore the normal menstrual 
physiology and thus, relieve pain during 
menstruation. 
   Basti can be affect on Kashtartava by 
following mechanisms; improves overall nutrition 
status of body, improves intestinal health and 
absorption, nourishing the system, increasing the 
immunity by detoxifying the system, and by action 
of active principle of drug it breaks the pathology. 
Thus, Basti will act not only the pain, but the entire 
whole the clinical picture of Kashtartava (physical & 
mental symptoms) of body by normalizing the 
functions of Vata. 
CONCLUSION 
1. Trivritadi Taila Anuvasan Basti per rectally act 
as Shodhana therapy effective in relieving 
Kashtartava. The effect of Trivritadi Taila 
Anuvasana Basti had prolonged effect in 
relieving cardinal and associated symptoms. 
Further it helps to reduce the possibility of 
recurrence which was evident on follow-up. 
2. The symptomatic improvement was found that 
average percentage of relief i.e. 63.67%. 
3. 05 (33.33%) patient showed excellent relief, 08 
(53.33%) patients showed significant relief, 02 
(13.33%) patients showed moderate relief and 
no any patient found with mild relief.  
4. Therapeutic effect of “Trivritadi Taila Anuvasan 
Basti”- showed relief by improvement with 
61.75% in pain intensity, 64.11% in pain 
duration, 54.30% in nature of pain,13.33% in 
menstrual flow duration, 24.16% in menstrual 
flow amount, 76.65% in associated symptoms, 
47.07% in VAS scale and 52.39% in Wong Baker 
facial grimace scale. 
5. Results prove that “Trivritadi Taila Anuvasan 
Basti” proved to be an effective & dependable 
remedy in the management of Kashtartava. 
6. Patients taken the “Trivritadi Taila Anuvasan 
Basti” very well with no complaints of any side 
effect or toxic effects.  
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